These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 36950081)

  • 1. Dimerized fusion inhibitor peptides targeting the HR1-HR2 interaction of SARS-CoV-2.
    Tsuji K; Baffour-Awuah Owusu K; Miura Y; Ishii T; Shinohara K; Kobayakawa T; Emi A; Nakano T; Suzuki Y; Tamamura H
    RSC Adv; 2023 Mar; 13(13):8779-8793. PubMed ID: 36950081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
    Liu S; Xiao G; Chen Y; He Y; Niu J; Escalante CR; Xiong H; Farmar J; Debnath AK; Tien P; Jiang S
    Lancet; 2004 Mar; 363(9413):938-47. PubMed ID: 15043961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the heptad repeat regions, HR1 and HR2, and design of a fusion core structure model of the spike protein from severe acute respiratory syndrome (SARS) coronavirus.
    Xu Y; Zhu J; Liu Y; Lou Z; Yuan F; Liu Y; Cole DK; Ni L; Su N; Qin L; Li X; Bai Z; Bell JI; Pang H; Tien P; Gao GF; Rao Z
    Biochemistry; 2004 Nov; 43(44):14064-71. PubMed ID: 15518555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides.
    Bosch BJ; Martina BE; Van Der Zee R; Lepault J; Haijema BJ; Versluis C; Heck AJ; De Groot R; Osterhaus AD; Rottier PJ
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8455-60. PubMed ID: 15150417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both heptad repeats of human respiratory syncytial virus fusion protein are potent inhibitors of viral fusion.
    Wang E; Sun X; Qian Y; Zhao L; Tien P; Gao GF
    Biochem Biophys Res Commun; 2003 Mar; 302(3):469-75. PubMed ID: 12615056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
    Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
    J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of SARS-CoV entry by peptides corresponding to heptad regions on spike glycoprotein.
    Yuan K; Yi L; Chen J; Qu X; Qing T; Rao X; Jiang P; Hu J; Xiong Z; Nie Y; Shi X; Wang W; Ling C; Yin X; Fan K; Lai L; Ding M; Deng H
    Biochem Biophys Res Commun; 2004 Jul; 319(3):746-52. PubMed ID: 15184046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
    Zhu Y; Yu D; Yan H; Chong H; He Y
    J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein.
    Yang K; Wang C; Kreutzberger AJB; Ojha R; Kuivanen S; Couoh-Cardel S; Muratcioglu S; Eisen TJ; White KI; Held RG; Subramanian S; Marcus K; Pfuetzner RA; Esquivies L; Doyle CA; Kuriyan J; Vapalahti O; Balistreri G; Kirchhausen T; Brunger AT
    Proc Natl Acad Sci U S A; 2022 Oct; 119(40):e2210990119. PubMed ID: 36122200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of an engineered N-terminal HIV-1 gp41 trimer with enhanced stability and potency.
    Dwyer JJ; Wilson KL; Martin K; Seedorff JE; Hasan A; Medinas RJ; Davison DK; Feese MD; Richter HT; Kim H; Matthews TJ; Delmedico MK
    Protein Sci; 2008 Apr; 17(4):633-43. PubMed ID: 18359857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico design of antiviral peptides targeting the spike protein of SARS-CoV-2.
    Ling R; Dai Y; Huang B; Huang W; Yu J; Lu X; Jiang Y
    Peptides; 2020 Aug; 130():170328. PubMed ID: 32380200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kaempferol inhibits SARS-CoV-2 invasion by impairing heptad repeats-mediated viral fusion.
    Gao J; Cao C; Shi M; Hong S; Guo S; Li J; Liang T; Song P; Xu R; Li N
    Phytomedicine; 2023 Sep; 118():154942. PubMed ID: 37421767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions.
    Veiga S; Yuan Y; Li X; Santos NC; Liu G; Castanho MA
    Biochim Biophys Acta; 2006 Jan; 1760(1):55-61. PubMed ID: 16290276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern.
    Xing L; Xu X; Xu W; Liu Z; Shen X; Zhou J; Xu L; Pu J; Yang C; Huang Y; Lu L; Jiang S; Liu S
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating vulnerability of the conserved SARS-CoV-2 spike's heptad repeat 2 as target for fusion inhibitors using chimeric miniproteins.
    Polo-Megías D; Cano-Muñoz M; Berruezo AG; Laumond G; Moog C; Conejero-Lara F
    Int J Biol Macromol; 2024 Mar; 262(Pt 2):130132. PubMed ID: 38354919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Engineered SARS-CoV-2 HR1 Trimer Exhibits Improved Potency and Broad-Spectrum Activity against SARS-CoV-2 and Its Variants.
    Bi W; Chen G; Dang B
    J Virol; 2022 Jul; 96(13):e0068122. PubMed ID: 35735997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a minimal peptide derived from heptad repeat (HR) 2 of spike protein of SARS-CoV and combination of HR1-derived peptides as fusion inhibitors.
    Liu IJ; Kao CL; Hsieh SC; Wey MT; Kan LS; Wang WK
    Antiviral Res; 2009 Jan; 81(1):82-7. PubMed ID: 18983873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and characterization of viral polypeptide inhibitors targeting Newcastle disease virus fusion.
    Zhu J; Jiang X; Liu Y; Tien P; Gao GF
    J Mol Biol; 2005 Dec; 354(3):601-13. PubMed ID: 16253271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heptad repeat 2-based peptides inhibit avian sarcoma and leukosis virus subgroup a infection and identify a fusion intermediate.
    Netter RC; Amberg SM; Balliet JW; Biscone MJ; Vermeulen A; Earp LJ; White JM; Bates P
    J Virol; 2004 Dec; 78(24):13430-9. PubMed ID: 15564453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.